MediPharm Labs to Export Large Shipment of GMP Cannabis Extract and Finished Products to Australia

Large shipment of GMP cannabis extract and 35,000 units of finished products further supports the Companya??s supply chain

Supply to help address demand for pharmaceutical-quality active ingredients and finished product in Australia

BARRIE, Ontario, March 24, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (a??MediPharm Labsa?? or the a??Companya??) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its subsidiary MediPharm Labs Australia Pty Ltd (a??MediPharm Labs Australiaa??) has received the necessary permits to import a large shipment of GMP cannabis oil from its other subsidiary MediPharm Labs Inc. (a??MediPharm Labs Canadaa??) upon receipt of export permits. This shipment will further support the Companya??s international supply chain and accelerates MediPharm Labs Australiaa??s ability to supply pharmaceutical-quality cannabis extracts and finished products to begin addressing Australian market demand for medicinal patients as well as for research and development.MediPharm Labs Canada has successfully completed previous exports to Australia.a??We have made a strong statement about our international intentions and our focus on the medicinal cannabis market in Australia since signing our first supply deal with AusCann Group Holdings Ltd. - a Australian pharmaceutical company with operations across all facets of the medicinal cannabis value chain,a?? said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. a??The most recent agreement with Compass Clinics is one of a pipeline of opportunities we have identified across Australia, and other emerging cannabis markets, that are available to us today and in the future as we receive other international regulatory permits and additional GMP certifications.a??a??Since opening the doors to our Australian facility late last year, we have made excellent progress with prospective customers to supply GMP concentrate and finished products to fuel downstream third-party programs,a?? said Warren Everitt, Chief Executive Officer, MediPharm Labs Australia. a??This shipment, which will include 35,000 units of finished product and our largest volume of GMP cannabis extract imported to date for further processing into soft gels and tincture bottles, accelerates our ability to start addressing the growing demand in Australia and from other jurisdictions.a??Increasing Requirements for Cannabis Imports to Australia
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2020    »